(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 16.66% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.83%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.48%.
Guardant Health's revenue in 2025 is $828,849,000.On average, 8 Wall Street analysts forecast GH's revenue for 2025 to be $114,929,541,340, with the lowest GH revenue forecast at $114,205,623,841, and the highest GH revenue forecast at $115,303,035,382. On average, 9 Wall Street analysts forecast GH's revenue for 2026 to be $138,371,748,339, with the lowest GH revenue forecast at $131,439,973,278, and the highest GH revenue forecast at $145,907,099,749.
In 2027, GH is forecast to generate $169,785,777,247 in revenue, with the lowest revenue forecast at $162,142,555,271 and the highest revenue forecast at $193,234,219,539.